Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Buss

Showing results (141-150 of 146) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 146 results.
Stem Cell Research & Therapy|May 4, 2025
Genome editing of TXNIP in human pluripotent stem cells for the generation of hepatocyte-like cells and insulin-producing islet-like aggregatesLeonardo Traini, Javier Negueruela, Bernat Elvira, et al.
Emerging Infectious Diseases|June 19, 2019
Mycobacterium bovis Infection in African Wild Dogs, Kruger National Park, South AfricaRoxanne L Higgitt, O Louis van Schalkwyk, Lin-Mari de Klerk-Lorist, et al.
Frontiers in Veterinary Science|February 15, 2021
Review of Diagnostic Tests for Detection of <i>Mycobacterium bovis</i> Infection in South African WildlifeNetanya Bernitz, Tanya J Kerr, Wynand J Goosen, et al.
BMJ Open|October 17, 2022
Cross-sectional study for COVID-19-related mortality predictors in a Brazilian state-wide landscape: the role of demographic factors, symptoms and comorbiditiesEmanuele Gustani Gustani-Buss, Carlos E Buss, Luciane R Cavalli, et al.
AIDS Patient Care and Stds|August 23, 2007
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretroviralsJacques Reynes, Keikawus Arastéh, Bonaventura Clotet, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2005
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trialsMark Nelson, Keikawus Arastéh, Bonaventura Clotet, et al.
Pageof 15

Showing results (141-150 of 146) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 146 results.
Stem Cell Research & Therapy|May 4, 2025
Genome editing of TXNIP in human pluripotent stem cells for the generation of hepatocyte-like cells and insulin-producing islet-like aggregatesLeonardo Traini, Javier Negueruela, Bernat Elvira, et al.
Emerging Infectious Diseases|June 19, 2019
Mycobacterium bovis Infection in African Wild Dogs, Kruger National Park, South AfricaRoxanne L Higgitt, O Louis van Schalkwyk, Lin-Mari de Klerk-Lorist, et al.
Frontiers in Veterinary Science|February 15, 2021
Review of Diagnostic Tests for Detection of <i>Mycobacterium bovis</i> Infection in South African WildlifeNetanya Bernitz, Tanya J Kerr, Wynand J Goosen, et al.
BMJ Open|October 17, 2022
Cross-sectional study for COVID-19-related mortality predictors in a Brazilian state-wide landscape: the role of demographic factors, symptoms and comorbiditiesEmanuele Gustani Gustani-Buss, Carlos E Buss, Luciane R Cavalli, et al.
AIDS Patient Care and Stds|August 23, 2007
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretroviralsJacques Reynes, Keikawus Arastéh, Bonaventura Clotet, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2005
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trialsMark Nelson, Keikawus Arastéh, Bonaventura Clotet, et al.
Pageof 15